ACC.24 — Investigator, Dr Steven Nissen joins us onsite to discuss the findings of a trial designed to evaluate the extent to which participants could safely and effectively select, purchase and use rosuvastatin calcium 5mg for a 6-month trial period (NCT04964544).

The TACTiC trial is a single-arm interventional, phase III self-selection and actual use study implementing a technology assisted tool within a web app. Around 1220 patients were enrolled in the study, with 1196 participants proceeding to the use phase. Primary outcome measures included the percentage of participants with an overall correct initial TASS outcome at the initial self selection, an overall correct final use outcome at the final use assessment, and percent baseline change in verified LDL-C. 

Findings first revealed at ACC showed that overall concordance between consumers and clinicians for initial self-selection was 90.7% (95% CI, 88.9 to 92.3). Final use assessment was concordant in 98.1% (95% CI, 97.1 to 98.8), with a mean change in LDL-C of -35.5% (95% CI, -36.6 to -34.3). Participants also had a high level of adherence, with no major safety issues.

Interview Questions:

1. What is the importance of this study?
2. What was the study design and enrolment?
3. Could you tell us more about how the participant would use the web app?
4. What were the key findings?
5. Based on these findings, what are the implications for clinical practice?
6. What are the knowledge gaps?
7. What are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.